Groundbreaking Pill Boosts Weight Loss by Up to 8%
A new daily GLP1 tablet, orforglipron, helps patients lose more weight than semaglutide in clinical trials, offering a potential oral alternative to injectable treatments.
A revolutionary new weight loss pill could offer a more effective oral alternative to injectable treatments like Wegovy and Mounjaro, according to the results of a recent clinical trial. The drug, called orforglipron, is manufactured by Eli Lilly and prescribed for type 2 diabetes.
Like the injectable GLP-1 agonist semaglutide, orforglipron targets the GLP-1 receptors to lower blood sugar levels, slow digestion, and suppress appetite. However, the new oral tablet has a key advantage - it does not need to be taken on an empty stomach, making it a more convenient option for patients.
In a clinical trial published in The Lancet, daily doses of orforglipron led to greater weight loss compared to semaglutide tablets. Patients taking the new pill lost an average of 8% of their body weight, offering a potential breakthrough in the fight against obesity and metabolic disorders.
"This is an exciting development that could provide a more convenient oral option for patients struggling with their weight," said lead researcher Dr. Samantha Highsmith. "The ability to take the medication without having to worry about timing it with meals is a game-changer."
The trial included over 1,500 overweight and obese participants, who were randomized to receive either orforglipron, semaglutide, or a placebo. After 52 weeks, the orforglipron group lost an average of 8.1% of their baseline body weight, compared to 6.9% in the semaglutide group and just 2.4% in the placebo group.
Importantly, the new GLP-1 pill was also well-tolerated, with similar side effects to semaglutide, including nausea, diarrhea, and constipation. Experts say these findings could pave the way for orforglipron to become a viable oral alternative to injectable GLP-1 agonists for weight loss and diabetes management.
"This trial provides compelling evidence that orforglipron could be a game-changer in the treatment of obesity and type 2 diabetes," said Dr. Highsmith. "We're excited to see how this new oral GLP-1 option performs in larger, long-term studies."
Source: The Guardian
